Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form
When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...
Fierce Pharma13h
Merck lays out subcutaneous Keytruda data in lung cancer amid patent brawl with Halozyme
Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating ...
Zacks Investment Research on MSN15h
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi
Ionis Pharmaceuticals IONS signed a license agreement with Sweden-based Sobi. Per the terms, Sobi will acquire exclusive ...
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
FDA Approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended De ...
BioPharma Dive1d
First Prader-Willi drug to reduce hunger approved by FDA
Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.
Wave to seek FDA accelerated approval for Duchenne candidate in 2026
Wave Life Sciences (NASDAQ:WVE) announced Wednesday its plans to file a New Drug Application (NDA) with the U.S. FDA in 2026 to seek the regulator’s accelerated approval for WVE-N531, an experimental ...
EQS-News: FDA Issues Nyxoah an Approvable Letter for its Genio® System
EQS-News: Nyxoah SA. / Key word (s): Miscellaneous FDA Issues Nyxoah an Approvable Letter for its Genio® System 26.03.2025 / 09:45 CET/CEST The issuer is solely responsible for the content of this ...
CorMedix (CRMD) Q4 2024 Earnings Call Transcript
CorMedix ( CRMD -24.88%) Q4 2024 Earnings Call Mar 25, 2025, 8:30 a.m. ET Good day, and welcome to the CorMedix Inc.
Palatin Technologies, Inc.: Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin ...